Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.
Epistemonikos ID: 662bf1c2d275c760d64aa7802f58970b348b315f
First added on: May 13, 2024